• A Corrigendum to this article was published on 01 April 2018

This article has been updated


The discovery of genetic mechanisms for resistance to obesity and diabetes may illuminate new therapeutic strategies for the treatment of this global health challenge. We used the polygenic 'lean' mouse model, which has been selected for low adiposity over 60 generations, to identify mitochondrial thiosulfate sulfurtransferase (Tst; also known as rhodanese) as a candidate obesity-resistance gene with selectively increased expression in adipocytes. Elevated adipose Tst expression correlated with indices of metabolic health across diverse mouse strains. Transgenic overexpression of Tst in adipocytes protected mice from diet-induced obesity and insulin-resistant diabetes. Tst-deficient mice showed markedly exacerbated diabetes, whereas pharmacological activation of TST ameliorated diabetes in mice. Mechanistically, TST selectively augmented mitochondrial function combined with degradation of reactive oxygen species and sulfide. In humans, TST mRNA expression in adipose tissue correlated positively with insulin sensitivity in adipose tissue and negatively with fat mass. Thus, the genetic identification of Tst as a beneficial regulator of adipocyte mitochondrial function may have therapeutic significance for individuals with type 2 diabetes.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 07 March 2018

    In the version of this article initially published, the colors of the lines were switched in the graph that shows the glucose infusion rates for wild-type mice and Adipoq-Tst transgenic mice in Figure 3b. The top line should be purple, and the bottom line should be black. The error has been corrected in the HTML and PDF versions of the article.


Primary accessions


Gene Expression Omnibus

Referenced accessions

Expressed Sequence Tag Database


  1. 1.

    , , & Prevalence and trends in obesity among US adults, 1999–2008. J. Am. Med. Assoc. 303, 235–241 (2010).

  2. 2.

    & Obesity prevalence in the United States—up, down or sideways? N. Engl. J. Med. 364, 987–989 (2011).

  3. 3.

    & Bigger bodies: long-term trends and disparities in obesity and body-mass index among U.S. adults, 1960–2008. Soc. Sci. Med. 75, 109–119 (2012).

  4. 4.

    et al. A polygenic model of the metabolic syndrome with reduced circulating and intra-adipose glucocorticoid action. Diabetes 54, 3371–3378 (2005).

  5. 5.

    et al. Mapping of obesity QTLs in a cross between mouse lines divergently selected on fat content. Mamm. Genome 11, 2–7 (2000).

  6. 6.

    , , & Congenic and bioinformatics analyses resolved a major-effect Fob3b QTL on mouse chr 15 into two closely linked loci. Mamm. Genome 21, 172–185 (2010).

  7. 7.

    et al. Long-term divergent selection on fatness in mice indicates a regulation system independent of leptin production and reception. FASEB J. 17, 85–87 (2003).

  8. 8.

    et al. A stratified transcriptomics analysis of polygenic fat and lean mouse adipose tissues identifies novel candidate obesity genes. PLoS One 6, e23944 (2011).

  9. 9.

    Rhodanese. Adv. Enzymol. 39, 327–368 (1973).

  10. 10.

    , & Which cyanide antidote? Crit. Rev. Toxicol. 39, 541–552 (2009).

  11. 11.

    , , & Rhodanese-mediated sulfur transfer to succinate dehydrogenase. Eur. J. Biochem. 72, 17–24 (1977).

  12. 12.

    & Interaction of rhodanese with mitochondrial NADH dehydrogenase. Biochim. Biophys. Acta 742, 278–284 (1983).

  13. 13.

    , & Rhodanese as a thioredoxin oxidase. Int. J. Biochem. Cell Biol. 32, 465–473 (2000).

  14. 14.

    Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol. Rev. 92, 791–896 (2012).

  15. 15.

    et al. Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy. Nat. Med. 15, 200–205 (2009).

  16. 16.

    et al. Mitochondrial enzyme rhodanese is essential for 5 S ribosomal RNA import into human mitochondria. J. Biol. Chem. 285, 30792–30803 (2010).

  17. 17.

    et al. Adipose-specific deletion of Tfam increases mitochondrial oxidation and protects mice against obesity and insulin resistance. Cell Metab. 16, 765–776 (2012).

  18. 18.

    et al. Mitochondrial complex III ROS regulate adipocyte differentiation. Cell Metab. 14, 537–544 (2011).

  19. 19.

    et al. MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat. Med. 18, 1539–1549 (2012).

  20. 20.

    et al. Increase or decrease hydrogen sulfide exert opposite lipolysis but reduce global insulin resistance in high-fat-diet-induced obese mice. PLoS One 8, e73892 (2013).

  21. 21.

    et al. Hydrogen sulfide from adipose tissue is a novel insulin resistance regulator. Biochem. Biophys. Res. Commun. 380, 153–159 (2009).

  22. 22.

    et al. Divergent physical activity and novel alternative responses to high-fat feeding in polygenic fat and lean mice. Behav. Genet. 38, 292–300 (2008).

  23. 23.

    et al. High-resolution genetic mapping using the Mouse Diversity outbred population. Genetics 190, 437–447 (2012).

  24. 24.

    , , , & Identification and characterization of a promoter cassette conferring adipocyte-specific gene expression. Endocrinology 151, 2933–2939 (2010).

  25. 25.

    et al. The fat-derived hormone adiponectin alleviates alcoholic and non-alcoholic fatty liver diseases in mice. J. Clin. Invest. 112, 91–100 (2003).

  26. 26.

    et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 484, 333–338 (2012).

  27. 27.

    et al. Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation. Pharmacology 82, 201–213 (2008).

  28. 28.

    et al. Rhodanese–thioredoxin system and allyl sulfur compounds. FEBS J. 275, 3884–3899 (2008).

  29. 29.

    et al. Essential role of mitochondrial function in adiponectin synthesis in adipocytes. Diabetes 56, 2973–2981 (2007).

  30. 30.

    et al. Genetics of gene expression and its effect on disease. Nature 452, 423–428 (2008).

  31. 31.

    et al. Decreased RB1 mRNA, protein and activity reflect obesity-induced altered adipogenic capacity in human adipose tissue. Diabetes 62, 1923–1931 (2013).

  32. 32.

    et al. Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. Int. J. Obes. Relat. Metab. Disord. 25, 8–15 (2001).

  33. 33.

    The genetic epidemiology of melanocortin 4 receptor variants. Eur. J. Pharmacol. 660, 156–164 (2011).

  34. 34.

    et al. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature 507, 371–375 (2014).

  35. 35.

    et al. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat. Genet. 43, 753–760 (2011).

  36. 36.

    et al. Meta-analysis identifies 13 new loci associated with waist–hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat. Genet. 42, 949–960 (2010).

  37. 37.

    et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat. Genet. 41, 1110–1115 (2009).

  38. 38.

    , , , & Molecular mechanisms of human lipodystrophies: from adipocyte lipid droplet to oxidative stress and lipotoxicity. Int. J. Biochem. Cell Biol. 43, 862–876 (2011).

  39. 39.

    et al. Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature 478, 97–102 (2011).

  40. 40.

    et al. Positional cloning of the mouse obese gene and its human homolog. Nature 372, 425–432 (1994).

  41. 41.

    , & Advances in comparative genetics: influence of genetics on obesity. Br. J. Nutr. 106 (suppl. 1), S1–S10 (2011).

  42. 42.

    , , , & Transgenic mice overexpressing the β1-adrenergic receptor in adipose tissue are resistant to obesity. Mol. Endocrinol. 11, 27–38 (1997).

  43. 43.

    & Brown and beige fat: development, function and therapeutic potential. Nat. Med. 19, 1252–1263 (2013).

  44. 44.

    et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336, 918–922 (2012).

  45. 45.

    et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 11, 554–565 (2010).

  46. 46.

    et al. RNA-seq alignment to individualized genomes improves transcript abundance estimates in multiparent populations. Genetics 198, 59–73 (2014).

  47. 47.

    , , & Measurement of size and turnover rate of body glucose pool by the isotope-dilution method. Am. J. Physiol. 187, 15–24 (1956).

  48. 48.

    & Three enzymatic activities catalyze the oxidation of sulfide to thiosulfate in mammalian and invertebrate mitochondria. FEBS J. 275, 3352–3361 (2008).

Download references


N.M.M. was supported by a Career Development Fellowship, an Institutional Strategic Support Fund award and a New Investigator Award from the Wellcome Trust (100981/Z/13/Z), a Research Councils UK Fellowship and a British Heart Foundation Centre of Research Excellence exchange award. We thank the Slovenian Research Agency for support (core funding P4-0220; project N5-0003 Syntol and J4-6804; all to S.H.) and for a Young Scientist Fellowship (J.B.). We acknowledge support of the British Heart Foundation Research Excellence Award in support of the contribution by the Bioinformatics Core (D.R.D.). T.M.S. received funding from the Federal Ministry of Economy, Family and Youth and from the Austrian National Foundation for Research, Technology and Development. G.A.C. was supported by the US National Institutes of Health grant R01GM 070683. J.M.F.-R. acknowledges funding from FIS PI11/00214. A.V.-P. was funded by the UK Medical Research Council (MRC) MDU, an MRC Programme grant, MRC DMC Core and MITIN (HEALTH-F4-2008-223450). We thank M. Wabitsch (University of Ulm) for the gift of the SGBS human preadipocyte cell line.

Author information


  1. University–British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, UK.

    • Nicholas M Morton
    • , Roderick N Carter
    • , Zoi Michailidou
    • , Clare McFadden
    • , Martin E Barrios-Llerena
    • , Matthew T G Gibbins
    • , Rhona E Aird
    • , Annalisa Gastaldello
    • , Lynne Ramage
    • , Gregorio Naredo
    • , Christopher J Kenyon
    • , Jonathan R Seckl
    • , Brian R Walker
    • , Scott P Webster
    •  & Donald R Dunbar
  2. Biotechnical Faculty, Animal Science Department, University of Ljubljana, Ljubljana, Slovenia.

    • Jasmina Beltram
    • , Gregor Gorjanc
    •  & Simon Horvat
  3. Metabolic Research Laboratories, Level 4, Wellcome Trust–MRC Institute of Metabolic Science, Addenbrookes Hospital, Cambridge, UK.

    • Sergio Rodriguez-Cuenca
    •  & Antonio Vidal-Puig
  4. Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomédica de Girona, Girona, Spain.

    • José Maria Moreno-Navarrete
    •  & José Manuel Fernandez-Real
  5. Department of Medicine, University of Girona, Girona, Spain.

    • José Maria Moreno-Navarrete
    •  & José Manuel Fernandez-Real
  6. Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Girona, Spain.

    • José Maria Moreno-Navarrete
    •  & José Manuel Fernandez-Real
  7. The Jackson Laboratory, Bar Harbor, Maine, USA.

    • Steven C Munger
    • , Karen L Svenson
    •  & Gary A Churchill
  8. Clinical Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

    • Maximilian Zeyda
    •  & Thomas M Stulnig
  9. Department of Internal Medicine, Touchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

    • Zhao V Wang
  10. The Medical Research Council (MRC) Centre for Reproductive Health, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, UK.

    • Alexander F Howie
  11. Department of Physiology, Institute of Biomedicine, University of Turku, Turku, Finland.

    • Aila Saari
  12. Central Animal Laboratory, University of Turku, Turku, Finland.

    • Petra Sipilä
  13. Icelandic Heart Association, Kopavogur, Iceland.

    • Vilmundur Gudnason
    •  & Valur Emilsson
  14. Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.

    • Antonio Vidal-Puig
  15. Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland.

    • Valur Emilsson
  16. National Institute of Chemistry, Ljubljana, Slovenia.

    • Simon Horvat


  1. Search for Nicholas M Morton in:

  2. Search for Jasmina Beltram in:

  3. Search for Roderick N Carter in:

  4. Search for Zoi Michailidou in:

  5. Search for Gregor Gorjanc in:

  6. Search for Clare McFadden in:

  7. Search for Martin E Barrios-Llerena in:

  8. Search for Sergio Rodriguez-Cuenca in:

  9. Search for Matthew T G Gibbins in:

  10. Search for Rhona E Aird in:

  11. Search for José Maria Moreno-Navarrete in:

  12. Search for Steven C Munger in:

  13. Search for Karen L Svenson in:

  14. Search for Annalisa Gastaldello in:

  15. Search for Lynne Ramage in:

  16. Search for Gregorio Naredo in:

  17. Search for Maximilian Zeyda in:

  18. Search for Zhao V Wang in:

  19. Search for Alexander F Howie in:

  20. Search for Aila Saari in:

  21. Search for Petra Sipilä in:

  22. Search for Thomas M Stulnig in:

  23. Search for Vilmundur Gudnason in:

  24. Search for Christopher J Kenyon in:

  25. Search for Jonathan R Seckl in:

  26. Search for Brian R Walker in:

  27. Search for Scott P Webster in:

  28. Search for Donald R Dunbar in:

  29. Search for Gary A Churchill in:

  30. Search for Antonio Vidal-Puig in:

  31. Search for José Manuel Fernandez-Real in:

  32. Search for Valur Emilsson in:

  33. Search for Simon Horvat in:


N.M.M. and S.H. conceived the experiments; N.M.M., J.B., R.N.C., Z.M., G.G., S.C.M., S.R.-C., C.M., M.E.B.-L., R.E.A., L.R., A.F.H. and S.H. performed experiments on in vivo models or samples; N.M.M., R.N.C., J.M.M.-N., M.T.G.G., C.M. and A.G. performed experiments on in vitro models; J.M.M.-N., V.G., J.M.F.-R. and V.E. provided and analyzed gene expression data from human adipose tissue; M.Z. and T.M.S. provided human adipose tissues; G.N. generated the TST inhibitor; A.S. and P.S. generated the Adipoq-Tst mice; Z.V.W. generated the adiponectin promoter DNA vector; D.R.D. performed bioinformatics analyses; S.C.M., K.L.S. and G.A.C. generated the Diversity Outbred mouse resources and data; S.R.-C., C.J.K., J.R.S., B.R.W., S.P.W., A.V.-P., J.M.F.-R., V.E. and S.H. discussed results and commented on the manuscript; and N.M.M. and S.H. wrote the paper.

Competing interests

N.M.M. and S.P.W. hold a target patent (WO2012/104589) for TST in weight-related disorders.

Corresponding authors

Correspondence to Nicholas M Morton or Simon Horvat.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–8 and Supplementary Tables 1–4

About this article

Publication history






Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing